Delek Group (DGRLY) Scheduled to Post Quarterly Earnings on Wednesday

Delek Group (OTCMKTS:DGRLY) is scheduled to be announcing its earnings results before the market opens on Wednesday, March 28th.

Shares of Delek Group (OTCMKTS:DGRLY) traded down $0.12 during mid-day trading on Friday, reaching $16.73. The company had a trading volume of 300 shares, compared to its average volume of 783. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 1.40. Delek Group has a twelve month low of $13.44 and a twelve month high of $24.76.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3294378/delek-group-dgrly-scheduled-to-post-quarterly-earnings-on-wednesday.html.

Delek Group Company Profile

Delek Group Ltd., an integrated energy company, explores for and produces natural gas in the Eastern Mediterranean's Levant Basin. It holds interests in Tamar and Leviathan projects with estimated reserves of approximately nine trillion cubic feet, as well as in partnerships' existing off-shore oil assets in the Mediterranean.

Earnings History for Delek Group (OTCMKTS:DGRLY)

Receive News & Ratings for Delek Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delek Group and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Lexington Realty Trust  Hits New 1-Year High and Low at $7.62
Lexington Realty Trust Hits New 1-Year High and Low at $7.62
Eyes Lips Face  Reaches New 52-Week High and Low at $17.14
Eyes Lips Face Reaches New 52-Week High and Low at $17.14
Contrasting Finish Line  & Foot Locker
Contrasting Finish Line & Foot Locker
Comparing Aeglea Bio Therapeutics  & Aileron Therapeutics
Comparing Aeglea Bio Therapeutics & Aileron Therapeutics
AerCap  and The Competition Head to Head Analysis
AerCap and The Competition Head to Head Analysis
Intesa Sanpaolo  Given Average Rating of “Buy” by Analysts
Intesa Sanpaolo Given Average Rating of “Buy” by Analysts


© 2006-2018 Ticker Report. Google+.